I first worked with John for nearly 15 years at my previous company, SCYNEXIS. In fact, John was the first full time finance employee, grew to become the Director of Finance, and helped take the company public in 2014 on the NASDAQ. Needless to say, it was a great experience for us all, and John was on the team that made it happen.
When I started a new company, Ribogenics, of course it made perfect sense for me to go back to John for Finance. He came the first day, and we were in business!
John is not only a great numbers guy; he also understands the Biotech ecosystem: investors both public and private, shareholders, partners, principal investigators, administrative support and scientists. He communicates easily with Board members and very quickly gained their trust. John also communicates well with scientists that may not have all the financial and operational knowledge required to build and grow a Biotech company. He is also very responsive in the demands of the stakeholders and good at prioritizing his job.
In a matter of 6 months, we put in place a complete team with the facility and raised $7M as seed money. I left the company at the end of 2021, but John stayed on to ensure that the evolution of Ribogenics was well managed.
Overall, when I have my next biotech project, I’m calling John!